Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,486Revenue $M578Net Margin (%)17.5Z-Score6.9
Enterprise Value $M2,241EPS $1.6Operating Margin %16.9F-Score5
P/E(ttm))22.8Cash Flow Per Share $1.6Pre-tax Margin (%)21.5Higher ROA y-yN
Price/Book3.310-y EBITDA Growth Rate %0Quick Ratio2.2Cash flow > EarningsY
Price/Sales4.05-y EBITDA Growth Rate %19.1Current Ratio2.4Lower Leverage y-yN
Price/Cash Flow9.5y-y EBITDA Growth Rate %34.9ROA % (ttm)11.8Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)15.7Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M70.0ROI % (ttm)14.8Gross Margin Increase y-yY

Gurus Latest Trades with WX

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
WXRon Baron 2014-03-31 Add0.01%$32.58 - $39.86
($36.74)
$ 35.5-3%Add 25.9%210,500
WXJohn Hussman 2014-03-31 Sold Out -0.03%$32.58 - $39.86
($36.68)
$ 35.5-3%Sold Out0
WXRon Baron 2013-12-31 Add0.02%$26.52 - $38
($31.52)
$ 35.513%Add 883.53%167,200
WXMario Gabelli 2013-12-31 Reduce$26.52 - $38
($31.52)
$ 35.513%Reduce -24.71%65,200
WXJulian Robertson 2013-12-31 Sold Out -2.4%$26.52 - $38
($31.52)
$ 35.513%Sold Out0
WXJohn Hussman 2013-12-31 Reduce-0.02%$26.52 - $38
($31.52)
$ 35.513%Reduce -50%10,000
WXRon Baron 2013-09-30 Add$20.23 - $28.48
($23.68)
$ 35.550%Add 54.55%17,000
WXMario Gabelli 2013-09-30 Reduce$20.23 - $28.48
($23.68)
$ 35.550%Reduce -26.05%86,600
WXJulian Robertson 2013-09-30 Reduce-0.85%$20.23 - $28.48
($23.68)
$ 35.550%Reduce -35.37%576,218
WXJohn Hussman 2013-09-30 Reduce-0.02%$20.23 - $28.48
($23.68)
$ 35.550%Reduce -50%20,000
WXRon Baron 2013-06-30 Buy $16.94 - $21.54
($19.52)
$ 35.582%New holding, 11000 sh.11,000
WXJulian Robertson 2013-06-30 Reduce-0.34%$16.94 - $21.54
($19.52)
$ 35.582%Reduce -13.99%891,618
WXJohn Hussman 2013-03-31 Buy 0.03%$15.44 - $17.91
($16.53)
$ 35.5115%New holding, 40000 sh.40,000
WXJulian Robertson 2012-06-30 Add0.28%$13.37 - $14.84
($14.21)
$ 35.5150%Add 6.51%1,154,418
WXJulian Robertson 2012-03-31 Reduce-1.67%$11.43 - $15.39
($12.73)
$ 35.5179%Reduce -24.88%1,083,818
WXMario Gabelli 2011-12-31 Reduce-0.01%$10.78 - $13.92
($11.9)
$ 35.5198%Reduce -28.82%250,200
WXJulian Robertson 2011-09-30 Add1.9%$11.56 - $17.26
($14.19)
$ 35.5150%Add 38.6%1,442,806
WXGeorge Soros 2011-06-30 Sold Out $16 - $18.89
($17.29)
$ 35.5105%Sold Out0
WXJulian Robertson 2011-03-31 Add0.24%$15.07 - $18.49
($16.38)
$ 35.5117%Add 5.71%1,095,772
WXGeorge Soros 2011-03-31 Buy 0.05%$15.07 - $18.49
($16.38)
$ 35.5117%New holding, 250000 sh.250,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

WX is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
WX Ron Baron 2014-09-30201,5000.290.03
WX Mario Gabelli 2014-09-3057,2000.080.01
Premium Most recent portfolio changes are included for Premium Members only!


WX: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about WX :

    Quarterly/Annual Reports about WX:

      News about WX:

      Articles On GuruFocus.com
      Baron Funds Comments on WuXi PharmaTech Feb 24 2014 
      Columbia Management's Top 5 New Buys Amid Buoyant Outlook Aug 12 2013 
      comment on WX Sep 15 2012 
      Stocks That Are Cheaper Than Julian Robertson Bought Jan 06 2012 
      Stocks That Julian Robertson Keeps Buying Dec 23 2011 
      Julian Robertson’s "smart idea, grounded on exhaustive research, followed by a big bet" Jun 24 2011 
      Julian Robertson’s Tiger Management Q1 Portfolio Update May 16 2011 
      Tiger Management Buys WX, CVC, THRX, Sells Apple Inc., Google Inc., Ebay Inc. Nov 15 2010 
      WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services Dec 09 2008 

      More From Other Websites
      WuXi Opening Offices in Boston and San Francisco Dec 15 2014
      WuXi Opening Offices in Boston and San Francisco Dec 15 2014
      WuXi PharmaTech Presents 2014 Life Science and Chemistry Awards Dec 08 2014
      WuXi PharmaTech Presents 2014 Life Science and Chemistry Awards Dec 08 2014
      WuXi AppTec Wins SCRIP Award for "Best Company in an Emerging Market" Dec 04 2014
      WuXi AppTec Wins SCRIP Award for "Best Company in an Emerging Market" Dec 04 2014
      WuXi PharmaTech Subsidiary Submits Application to the National Equities Exchange and Quotations in... Dec 03 2014
      Another record setting day again on Wall Street Nov 21 2014
      Wuxi Pharmatech Cayman Inc Earnings Call scheduled for 8:00 am ET today Nov 13 2014
      WuXi PharmaTech Announces Third-Quarter 2014 Results Nov 12 2014
      WuXi PharmaTech Announces Third-Quarter 2014 Results Nov 12 2014
      WuXi AppTec Announces Enhanced Genomics Services for Chinese Researchers Nov 12 2014
      WuXi AppTec Announces Enhanced Genomics Services for Chinese Researchers Nov 12 2014
      Q3 2014 WuXi Pharmatech (Cayman) Inc Earnings Release - After Market Close Nov 12 2014
      WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2014 Annual General Meeting Nov 11 2014
      WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2014 Annual General Meeting Nov 11 2014
      WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax Oct 30 2014
      WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax Oct 30 2014
      WuXi Congratulates TaiMed Biologics on Receiving Orphan Drug Designation for Ibalizumab from U.S.... Oct 23 2014
      WuXi Congratulates TaiMed Biologics on Receiving Orphan Drug Designation for Ibalizumab from U.S.... Oct 23 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK